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Abstract
Medication-overuse headache (MOH) is a worldwide health problem with a prevalence 
of 1–2%. It is a severe form of headache where the patients often have a long history of 
unsuccessful headache treatments. MOH is characterized by chronic headache and the 
overuse of different headache medications. Through the years, withdrawal of the over-
used medication has been recognized as the treatment of choice. However, currently, 
there is no clear consensus regarding the optimal strategy for the management of MOH. 
Treatment approaches are based on expert opinion rather than scientific evidence. This 
chapter focuses on an overall discussion of medication abuse as a novel pain pathway in 
headaches.
Keywords: headache treatment, migraine, medication-overuse headache, pain pathways, 
chronic headache
1. Introduction
Headache is one of the first causes for pain consultation in primary care settings and one of 
the major complaints of pain made at the neurology clinic [1]. Overall it is estimated that 
4% of the general population suffer from migraine, representing at least 280,000,000 people 
requiring treatment only for just one cause of cephalea [2]. If the number of all other headache 
causes is added to the total number of migraine patients, the number of people requiring 
treatment for headaches represents almost one-sixth of the global population.
Due to the high number of patients as well as the varied causes of headaches, cephalea treat-
ments are varied ranging from mild, over-the-counter painkillers such as paracetamol [3], to 
high complex molecules, intended to act as neuromodulators and prevent pain crisis, such 
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as topiramate [4], and sometimes further requiring nonopioid and opioid analgesics such 
as ketoprofen [5] and codeine [6]. With so many people suffering from headaches and hav-
ing such a varied set of available drugs for treatment, it is no surprise that the problem of 
overuse and abuse of such treatments exists, leading to the appearance of secondary adverse 
effects such as the development of new pain pathways, among a certain group of patients. To 
understand the complexity of a problem like this, it is necessary to gain a deep knowledge of 
headache physiopathology, pharmacological options, and treatment guidelines, in order to 
identify the reasons leading to cephalea treatment overuse, and the arising of such a tricky 
problem such as the development of new pain pathways.
2. Classification of headaches
Although the concept of cephalea has mostly remained the same since it was first used to 
describe this type of disorder, its classification has been evolving continuously in line with 
modern physiopathological and pharmacologic concepts. The term cephalea or cephalalgia 
denotes pain located anywhere in the head and neck, regardless of the etiology; however, 
such a vast subject requires a very detailed classification scheme to determine which would 
be the best treatment for each type. Headaches are divided into two major groups: primary 
headaches and secondary headaches. Primary headaches are those appearing spontaneously 
with no association to any other disease or medical condition, while secondary headaches are 
those appearing in close temporal relation to another condition known to produce cephalea 
[7]. The main difference between both groups is whether or not an association is found with 
another cause, thus primary headaches have an intrinsic physiopathology while secondary 
cephalea is the consequence of another disease, trauma, or medical condition.
Primary cephalalgia is divided into four major categories:
(1)  Migraine
(2) Tension-type headache
(3) Trigeminal autonomic cephalalgias
(4)  Other primary headache disorders [8] 
While secondary cephalea has eight:
(1)  Headache attributed to trauma or injury to the head and/or neck
(2) Headache attributed to cranial or cervical vascular disorder
(3) Headache attributed to nonvascular intracranial disorder
(4) Headache attributed to a substance or its withdrawal
(5) Headache attributed to infection
(6) Headache attributed to disorder of homoeostasis
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(7) Headache or facial pain attributed to disorder of the cranium, neck, eyes, ears, nose, si-
nuses, teeth, mouth, or other facial or cervical structure
(8)  Headache attributed to psychiatric disorder [9]
From the above-mentioned cephalea types, migraine and tension-type headaches represent 
up to 80% of all cases [10]; however, it is important to recognize all other types of cephalea so 
as to avoid misdiagnosis and treatment errors since these could be the first steps toward the 
overuse and abuse of headache treatment drugs.
3. Headache physiopathology
A detailed description of the physiopathology of each type of headache goes far from the 
reach of this chapter, thus the discussion will be focused on the most common subtypes; 
migraine and tension-type headache as well as on a common feature for each cephalea type: 
the pain pathway.
3.1. Physiopathology of migraine
Despite being the most common cause of headache, the underlying pathogenesis of migraine 
is not known and every day, new data is being made available which aid in the clarification of 
the possible processes behind such a major public health problem.
Once considered a cephalalgia of vascular origin involving intracranial blood vessel dilata-
tion, recent data reveals that the physiopathology of migraine is much more complex; abnor-
mal modulation of brain nociceptive systems [12], brain excitability, recurrent activation, and 
sensitization of the trigeminovascular pathway [13] all work together not only to produce but 
also to prolong the migraine.
The integration of the above-mentioned factors is shown in Figure 1, where the interaction 
and upregulation of each element over the other is made clear.
Moreover, Figure 1 demonstrates why there are so many available migraine treatments, as 
each one has to work on a very narrow cluster of the whole pathogenic chain and why the 
effect of a particular therapy may diminish over time due to the upregulation and potentia-
tion between different pathological events associated with migraine.
The good news behind such a complex physiopathology is the high number of therapeutic 
targets available to work with, rendering the therapeutic options almost infinite. Although 
the ideal treatment would be one that could act over all the mechanisms, or at least the most 
important one, unfortunately, such a treatment is far from being available, and current knowl-
edge points to what seems to be the convergence point of all migraine pathogenic mecha-
nisms: serotonin [14]. Abnormally low levels of this important neurotransmitter seem to be 
the cause of at least two of the pathological aspects: blood vessel dilation and brain hyper-
excitability; hence, it is not surprising to find that there is a remarkable therapeutic effect by 
serotonin agonists on migraine.
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3.2. Physiopathology of tension-type headaches
Even though migraine represents a major public health concern and is the leading cause 
of headache, tension-type headache should not be underestimated since it represents 
Figure 1. The pathways of migraine [11].
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the second most common cause of cephalalgia with a prevalence of 46.9% in the general 
population [15], and provides the potential for a great field of study as tension-type head-
aches may be present in an acute scenario (known as episodic tension-type headache) or 
chronically, being called in such cases chronic tension-type headache. The most interesting 
fact regarding this dual presentation profile is that in some people tension-type headache 
remains acute and sporadic while some others progress toward a chronic condition. At the 
initial stage, both episodic and chronic tension-type headaches share a common patho-
physiological pattern associated with scalp and head muscles chronically contracting as 
well as certain neck movements [16], these are usually identified as the triggers and are 
the targets for therapy in the past; however, recent investigations have shown that chronic 
muscle contraction alone is not enough to cause a pain crisis, but it also includes the pres-
ence of central nervous system factors such as a hypersensitivity to pain stimuli which 
causes a tension-type headache to evolve from just a simple contraction [17] to a chronic 
disorder affecting quality of life [18].
It is possible that at the very beginning all tension-type headaches begin this way but when 
there is increased excitability of the central nervous system generated by repetitive and sus-
tained pericranial myofascial input [19] permanency occurs and upregulation creates a cycle 
of chronic tension-type headache, with lower stimuli requirements needed to trigger the next 
pain crisis. At the molecular level, chronic tension-type headache has been associated with 
low serotonin levels [20] acting as an upregulator in the case of migraine, on the other hand, 
there is the recent description of nitric oxide playing a role in both migraine and tension-type 
headaches, acting as a cranial and extracranial blood vessel dilator as well as a central nervous 
system sensitizer, these findings have led to a hypothesis about a common pain pathway 
shared by all primary chronic cephalalgias or at least between the two major groups, migraine 
and chronic tension-type headache [21].
4. Headache pain pathway
It is a well-known fact that cerebral tissue has no pain receptors, making it impossible to gen-
erate painful stimuli directly from the brain; most head and neck tissues such as bone, muscle, 
skin, and even blood vessels share a common innervation pattern where nociceptive C and 
A-delta fibers from the first root of the trigeminal nerve are involved as seen in Figure 2.
The aforementioned common innervation pattern may cause headache to arise from almost 
any head structure from muscles to meningeal membranes progressing to a chronic condi-
tion based on preexisting genetic, biochemical, and behavioral characteristics of each indi-
vidual. Once the pain has become chronic, at least two molecular events have been identified 
as responsible (totally or partially) for pain upregulation: low serotonin levels and high nitric 
oxide, both of them upregulating pain pathways in at least two major headache groups: 
migraine and chronic tension-type cephalalgia [23]. Based on the above, positive strides can be 
made toward the development of new drugs intended not only to treat pain but also to prevent 
it [24] since the existence of both a common neurologic pain pathway as well as shared molec-
ular features among major primary headache groups provides that possibility; moreover, it 
Headache of Analgesic Abuse as a Cause of New Pain Pathways Development
http://dx.doi.org/10.5772/67244
145
could be possible to treat different primary headache types with a single drug working on key, 
shared points of the pain pathway [25]; however, more extensive research as well as a deeper 
understanding of different pain pathway integration is needed to achieve such goals; primary 
headache treatments still focus on two main targets: pain control and crisis prevention.
5. Pharmacological options for headache treatment
It is a well-known fact that prevention of a medical condition is usually the best approach 
because it tends to be easier, cheaper, and cost effective; hence the aim of primary headache 
treatment should be focused on such a target. However, at this moment, prevention strategies 
for primary headache are not 100% reliable and the failure rates are high [26] leading to the 
use of palliative measures in order to relieve patients’ suffering derived mainly from migraine 
and tension-type headache.
Figure 2. Blood vessel innervation pattern and migraine associate pain pathways [22].
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In this regard, current pharmacological approaches include two major groups of action: 
pain relief and brain modulation, each one aimed to act on a particular stage. Although 
pain relief should be the last resort and be used only when modulation and prevention 
have failed, this is the main therapeutic approach in real life, treating the problem once 
it has fully showed up; the reason behind such behavior could be related to the ancient 
approach toward headache based on pain relief, used for decades when primary headache 
was not known as it is today and no other therapeutic option was available; and although 
there may be numerous and powerful effective pain killers and analgesics available, this 
option should be restricted only to cases where prevention has failed; always giving pri-
ority to novel, preventive therapies offering patients a better quality of life [27]. With the 
everyday increase in knowledge on primary headache pathophysiology, neurochemistry, 
and pain pathways, modern, current treatments of primary headaches intended to act as 
brain modulators have gained popularity because they are more expensive than conven-
tional pain killers, such drugs are able to give patients a better quality of life, decreasing the 
negative impact of headache on both personal and work commitments [28]. Novel migraine 
and tension-type headache treatments exert their action in several ways but with a common 
goal: reduction of pain crisis by downregulating sensitized brain pathways, which usually 
act as a trigger or maintain the headache pain crisis, leading to an overall reduction of acute 
primary headache and thus a drop in the requirements for over-the-counter (OTC) painkill-
ers and prescription analgesic use.
According to the U.S. Headache Consortium the scope of modern migraine treatment must 
be to:
 - Reduce attack frequency and severity
 - Reduce disability
 - Improve quality of life
 - Prevent headache
 - Avoid headache medication escalation
 - Educate and enable patients to manage their disease [29]
It is clear that the use of OTC painkillers and analgesics are a last resort and is considered to 
be a damage control strategy, leading the way not only to better control of the migraine but 
also to a reduction in headache medication overuse [30].
Hence, the aforementioned medications may be extrapolated for use with tension-type and 
cluster headaches due to them having similar pathological pathways and neurotransmitters 
shared by the three major causes of primary headache.
The modern approach toward current headache management is shown in Figure 3.
After careful analysis of Figure 3, one can deduce that primary headaches still remain a diag-
nostic and therapeutic challenge, where a misdiagnosis or improper drug selection could lead 
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to treatment failure, with unexpected consequences not only by reducing the patient’s quality 
of life but also due to the possible development of complications, thus it is mandatory to have 
a clear idea of available treatments and their mechanisms of action in order to properly select 
one or another option when necessary.
Figure 3. Assessment and management of patients with primary headaches [31].
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5.1. Comparison of the mechanism of action of different primary headache treatments
Due to the complex underlying pathologic mechanisms regarding primary headaches, com-
mon pain pathways, as well as the different drugs types and mechanisms of action, it is 
best to evaluate the most effective treatment for a particular patient by using a comparison 
chart because even though general guidelines may be helpful, primary headache treatment 
still needs to be individualized and adapted to the particular requirements of each patient. 
Modern therapeutic options for primary headaches as well as their primary and complemen-
tary mechanisms of action and indications are summarized in Table 1.
Preventive and abortive treatments
Drug* Drug class Mechanism of action Indication
Amitriptyline [32]
(Nortriptyline)
Tricyclic antidepressants Primary: Serotonin reuptake 
inhibitor
Secondary: Still not properly 
known
Migraine (prevention)
Tension-type headache 
(prevention) [33]
Sumatriptan [34]
(Rizatriptan, Naratriptan, 
Eletriptan, Donitriptan, 
Almotriptan, Frovatriptan, 
Avitriptan, Zolmitriptan)
Triptans Primary: Selective Intracranial 
Blood Vessels constrictor 
acting as 5-HT1B and 5-HT1D 
serotonin receptors agonists
Secondary: Blockage of 
sensitized neural pathways [35]
Migraine (Pain crisis 
abortive medication)
Cluster headache (Pain 
crisis abortive medication)
Ergotamine
(Dihydroergotamine)
Ergopeptine Primary: Constriction of 
intracranial extra cerebral 
blood vessels working as 
5-HT1B receptor agonist and 
5-HT1D serotonin receptor 
blocker
Secondary: Inhibition of 
trigeminal neurotransmission
Migraine (Long lasting 
pain crisis) [36]
Propranolol [37]
(Nadolol, Timolol, 
Metoprolol, Atenolol)
Beta blockers Primary: Inhibition of 
intracranial extra cerebral blood 
vessels dilation through Beta 
adrenergic receptors blockage
Migraine (prevention)
Cluster Headache 
(prevention)
Valproic Acid
- valproate -
Antiepileptic drug not 
chemically related to other 
anticonvulsivant
Primary: Under investigation, 
it’s presumed that valproate 
may decrease nerve 
impulse transmission in 
previous sensitized pain 
pathways [38]
Migraine (Pain crisis 
abortive medication) [39]
Cluster Headache 
(Preventive) [40]
Topiramate Anticonvulsant Primary: Modification of several 
receptor-gated and voltage-
sensitive ion channels, including 
voltage-activated Na+ and Ca2+ 
channels and non-NMDA 
receptors [41]
Secondary: Modulation 
of gamma-aminobutyric 
acid- (GABA-) and/
or glutamate-mediated 
neurotransmission [42]
Migraine (prevention) [43]
Cluster headache 
(Adjunctive treatment) [44]
Tension-type headache 
(Prevention) [45]
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Different options are available to stop migraine attacks: acute, symptomatic treatment. According 
to recent clinical evidence, the common approach to treating a migraine attack is based on early 
intervention when the pain is still mild, which can result in shortening the time to achieve a 
pain-free response. A proper clinical approach, individual considerations for each patient and a 
quick view of  the guidelines may help to provide the best treatment for specific case [56].
5.2. Acute, sporadic headache treatment
Many people in the general population have experienced at least one headache crisis which 
is usually of no major concern since it may be treated with OTC painkillers with no further 
complications or sequelae. In fact, sporadic headaches need no medical attention and most 
cases are resolved by the patients themselves [57].
The most popular treatments for this type of acute, primary headache include paracetamol, 
when pain intensity is mild to moderate, and aspirin or any other NSAIDs such as ibuprofen, 
for high intensity headaches; it usually requires no more than a single dose to control the crisis 
[58]. From this perspective, acute sporadic headache treatment represents no problem at all 
Preventive and abortive treatments
Drug* Drug class Mechanism of action Indication
Rescue treatments (pain control)
Acetylsalicylic acid 
- Aspirin-**
NSAIDs Primary: COX-1 and COX-2 
inhibition
Tension-type headache 
(Rescue) [46]
Paracetamol** Mild analgesic Primary:
- Suppression of signal towards 
the dorsal horn from the 
peripheral nerves by blocking 
TRPA1-receptors (peripheral 
pain pathway blockage) [47]
- Inhibition of the reuptake of 
the endogenous cannabinoid/
vanilloid anandamide by 
neurons down regulating TRPV1 
nociceptor stimulation (central 
pain pathway blockage) [48]
Tension-type Headache 
(Rescue)
Migraine (Rescue) [49]+
Ibuprofen**
(Ketoprofen)
NSAIDs Primary: COX-2 inhibition [50] Tension-type headache 
(Rescue) [51]
Migraine (Rescue) [52]
Butorphanol Opiates Primary: Binding to central 
opioids receptors, down 
regulating central pain 
stimuli transmission [53]
Migraine (Rescue)++
*The model drug is shown as the main drug even when there are other molecules sharing the same mechanism of action 
(shown below the main category group in brackets).
**Even when each one has good therapeutic effect using alone, recent investigations suggest that combination of fixed 
doses of paracetamol, NSAIDs, and caffeine is more effective that any single drug alone [54].
+Some studies show that the addition of metoclopramide to paracetamol potentiates its effects on migraine patients [49].
++Despite the well-known analgesic effect of opiates, there is no strong clinical trials supporting their use in migraine, 
thus its use must be considered when all other available therapies have failed [55].
Table 1. Comparison of different primary headache available treatments.
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since the risk of complications derived from treatment use and abuse are low or even null; 
however, many tension-type headaches begin as sporadic ones and with time they progress 
to a classic chronic cephalalgia. On the other hand, many undiagnosed migraine patients with 
low intensity crisis make it through the year with a very low frequency of intense attacks (less 
than one a month) and may handle their headache as a sporadic one with relative success 
in its initial stages [59] but sooner or later, a chronic pattern will develop, requiring medical 
assistance, with treatment optimization and monitoring in order to avoid headache treatment 
abuse-related problems. Since paracetamol, aspirin, ibuprofen, and various other OTC drugs 
are effective, safe treatments for acute headache crisis [60], there are no major concerns regard-
ing the risks and so the use of such medication must not be discouraged because it is not a threat 
for patients; however, the underdiagnosis of migraine as well as tension-type headaches must 
be addressed. Many undiagnosed patients are left to deal with, on their own, against complex 
headaches which do require professional counseling in order to obtain proper relief and avoid 
headache overuse treatment-related problems, which are much more difficult to manage.
5.3. Chronic headache treatment
It is clear that a common, acute headache crisis presents no danger neither for the patient nor 
public health; however, when headache crises become more frequent requiring regular self-med-
ication, often with poor outcomes and when such crises are accompanied by other symptoms 
such as auras or nausea, it becomes compulsory on the part of the physician to evaluate the 
patient for more complex etiologies, more than just a sporadic headache, in this case, a thorough 
medical consultation is mandatory in order to properly assess the patient, providing a diagno-
sis and a treatment intended not only to relieve pain but also to prevent recurrences. As stated 
previously, a high percentage of migraine sufferers have had no formal diagnosis of the disease 
[61], while some others progress from acute crisis of the tension-type headache to a chronic pat-
tern when sensitization pathways become activated [62]; in both cases, symptoms may develop 
so subtly that patients are not fully aware of the disease state and may remain on the same self-
medicating strategy for years despite the poor outcome. Even worse, this increases the chances 
of developing complications associated with improper management of chronic cephalea and 
treatment abuse. In this regard, the best strategy to conquer this problem is education. Beyond 
pharmacological treatment, it is important to inform the general public about primary headaches 
and how such entities may be easily confused with a banal headache and explain why their 
insidious evolution may render them undiagnosed for a long period of time; it is mandatory to 
educate patients about their diseases, giving emphasis to how important preventive medications 
are as primary therapy intended to reduce the likelihood of pain crises and increase their quality 
of life, leaving analgesics and OTC painkillers as a last resort when prevention has failed [63].
Implementation of education programs about headaches from school and on to the general pub-
lic can be a key strategy to address the problem of underdiagnosis, misdiagnosis, and improper 
management of headaches [64]. The aim of such programs must be to encourage people to seek 
medical advice when certain headache patterns show up and this will help direct them to special-
ized physicians who will provide the appropriate care and counseling [65, 66]. Unfortunately, 
due to an increase in the access to over-the-counter treatments, low income, lack of medical secure 
coverage, and unawareness about migraine, tension-type headaches, and other primary cepha-
lalgias, the trend is moving toward self-medication instead of professional counseling [67] which 
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has led to the improper use or even abuse of headache medications; however, once a headache 
patient has reached regular medical care, efforts must be made in order to enhance doctor-patient 
communication and provide as much information as possible to the patient [68] since having an 
in-depth knowledge of these diseases will lead to better management [69]; once patients are aware 
of a medical condition such as primary headaches, they act as multipliers among their families, 
relatives, friends, and coworkers [70], making it easier to catch public interest on a public health 
problem like migraine and other primary headaches. It remains clear that education and informa-
tion play a key role in addressing chronic primary headache; however, once a patient has grasped 
these important concepts and the physician has given a diagnosis, it is necessary to utilize the 
right tools in order to correctly estimate the impact of headache on their quality of life [71] and to 
choose the right treatment for each individual case; otherwise, using standardized protocols even 
in the medical community may present the danger of improper treatment and abuse of certain 
medications [72]. To accomplish such a delicate task, health care providers rely on many tools 
such as MIDAS (Migraine Disability Assessment Score) intended to objectively evaluate head-
ache frequency, pain intensity, and associated symptoms so as to measure not only the impact of 
headache on quality of life but also to assess treatment outcomes leading to a personal, tailored 
treatment regimen for each patient [73]. Once the diagnosis has been achieved and the impact on 
both quality of life and productivity is assessed [74], the precise treatment can then be chosen for 
each patient. It is important to note that the main goal of chronic primary headache treatment is to 
lower as much as possible the number of pain crises (preventive treatment), the secondary objec-
tive is to end a possible a crisis once it has evolved and has been triggered (abortive treatment), 
and finally, rescue patients once a crisis has stopped (rescue treatment). Long-term treatment 
options for each step of therapy have widened, providing physicians with a variety of drugs 
acting on different key points in the pathological chain as seen in Table 1. Everyday there is the 
development of a more complex therapeutic arsenal against migraine as well as other primary 
headaches. Gaining the proper knowledge of all available treatment options may be a challenge 
to even the most expert specialists; thus, this report has rendered the task easier by providing an 
organized list of all available therapeutic options summarized in Tables 2 and 3.
First-line preventive medications for migraine
Drug name FDA-approved Formulation Dosage
Onabotulinum toxin A Yes Injection Dose: Varies (FDA official dose is 155 units 
via 31 injections every 3 months)
Anticonvulsants
Topiramate Yes Oral Total dose varies from 25 or 50 mg/day up to 
400 mg/day
Valproic or divalproex sodium Yes Oral Usual dose: 500–1000 mg/day in divided doses
B-blockers
Propranolol Yes Oral 60–120 mg/day
Metoprolol No Oral 25–100 mg/day
Atenolol No Oral 25–50 mg/day
Nebivolol No Oral 2.5–10 mg/day
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First-line preventive medications for migraine
Drug name FDA-approved Formulation Dosage
Tricyclic antidepressants
Amitriptyline
Nortriptyline
No Oral Stating dose: 10 mg at bedtime, titrate up to 
25–50 mg at night. Maximum dose: 150 mg/
day
Doxepin No Oral Starting dose: 10 mg at bedtime, titrate up to 
25–50 mg/day. Maximum dose: 150 mg/day
Protriptyline No Oral 5–20 mg/day
NSAIDs*
Naproxen No Oral 500–550 mg/day; maximum dose 1000–1100 
mg/day
Calcium channel blocker
Verapamil No Oral 120 mg/day slow-release tablet, titrate to 240 
mg/day
Table reproduced and adapted from the original source [75].
*Other NSAIDs are useful as well.
Table 2. First-line migraine preventive medications.
Second-line migraine preventive therapy*
Drug name FDA-approved Formulation Dosage
Antiseizure medications
Gabapentin No Oral Usual dose: 600–2400 mg/day
Some patients do well on low doses (100–300 mg/day)
Pregabalin No Oral 25 mg bid to 150 tid
Muscle relaxants
Cyclobenzaprine No Oral 5–10 mg/day
Tizanidine No Oral Usual dose: 2–4 mg every night; patients start with 
¼ to ½ tablet. May be increased to 12 mg/day
Antidepressants
Desvenlafaxine No Oral 50–100 mg/day
Duloxetine No Oral 30–60 mg/day
Venlafaxine No Oral 75–225 mg/day
Natural agent
Purified butterbur No Oral 100–150 mg/day
Table reproduced and adapted from the original source [76].
*Polypharmacy also is commonly used as second-line treatment of migraine (i.e., amitriptyline with propranolol or 
amitriptyline with valproic acid).
Table 3. Second line migraine preventive medications.
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With the above information in mind it makes it easier to decide what the best options are for 
each patient; however, migraine treatment as well as the treatment for chronic tension-type 
and other primary cephaleas must be chosen considering each particular patient condition, 
available treatments at their location, exposure to triggers, and so on [77]. Usually this type 
of initial approach is enough to achieve adequate control of symptoms but if unsuccessful, it 
becomes mandatory to prioritize which attributes from each drug are better for a particular 
patient in order to choose the best mix of pharmacologic therapy [78]. In this regard, when 
precise medical treatment has been chosen, it is very important to measure its impact [79], not 
doing so could run the risk of the patient receiving a useless treatment over a long period of 
time leading to further problems regarding that particular treatment as well as future thera-
pies. In this sense, it is also important to address the patient’s expectations of the treatment 
in order to be able to provide not only a good outcome but also to gauge what the patient is 
expecting from treatment regarding tolerability, effectiveness, side effects, and other aspects 
of therapy; otherwise, there is a high risk of noncompliance which may lead patients toward 
self-medication and all the implied risk attributed to it. In addition, it is necessary to be aware 
of the adverse effects because even though the therapeutic action is good enough to improve 
the quality of life, the development of adverse side effects may lead to therapy discontinua-
tion. A summary of the main adverse side effects associated with the main treatment catego-
ries are summarized in Tables 4–6.
It remains clear that proper treatment selection, impact evaluation, and limiting the side effects 
are all challenging tasks requiring highly specialized medical staff with adequate experience; 
otherwise, the outcome may not be satisfactory leading to possible therapy discontinuation, 
Medications for abortive therapy
Drug name Possible side effects
Ergot
Dihydroergotamine mesylate
Nausea, numbness of fingers and toes
Triptans
Sumatriptan succinate*
Side effects for all the triptans are similar
This class of drugs is well tolerated but the more 
common side effects may include:
Nausea, headache, sleepiness, dry mouth, dizziness, 
fatigue, hot/cold sensations, chest pain, and flushing
Other potential side effects that rarely occur include:
Head, jaw, chest and arm discomfort/tightening/tingling; 
throat discomfort, muscle cramps, and flushing
Zolmitriptan*
Rizatriptan*
Naratriptan+
Almotriptan malate*×
Frovatriptan succinate+
Eletriptan hydrobromide*
*Short-acting.
+Long-acting.
×FDA approved for teens ages 12–18.
Table reproduced and adapted from the original source [80].
Table 4. Side effects of main first-line migraine abortive drugs.
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self-medication, and the use of alternative treatments whose effectiveness and safety may not 
be well known. Unfortunately, there are still many cases worldwide of misdiagnosis, errone-
ous management, and self-medication due to lack of specialized medical assistance. All these 
factors are a “recipe for disaster” since many headache rescue treatments are available over 
the counter and thousands, perhaps millions of people try to fight alone against migraine, 
tension-type headache, and other primary cephaleas, lacking proper advice, leading to one of 
the worst complications of primary cephalalgias: drug overuse and abuse.
Medications for preventive therapy
Drug name Possible major side effects Instructions when used for headaches
Nonsteroidal anti-inflammatories
Naproxen sodium
GI** upset, GI bleeding, nausea, 
vomiting, rash and change in liver 
function, rebound headache
Is take twice a day, every day, for 
headache prevention
Tricyclic antidepressants
Imipramine HCl
Amitriptyline HCl
Dizziness, drowsiness, dry mouth, 
weakness, weight gain
Fatigue, dry mouth, weight gain and 
constipation
Frequently started at low dosages 
and slowly increased
Frequently started at low dosages 
and slowly increased to a therapeutic 
level; taken by night, EKG*** optional
Antihistamines
Cyproheptadine HCl
May induce sleep or may shorten 
migraine attack, weight gain, 
drowsiness
Usually started at low dosages and 
slowly increased; often taken at 
bedtime
Selective serotonin receptor 
inhibitors (SSRIs)*
Fluoxetine HCl
Nausea, dry mouth, increased 
appetite, agitation
Usually started at low dosages and 
slowly increased; usually taken at 
morning
Beta blockers
Atenolol
Fatigue, depression, weight gain, 
memory disturbance, faintness and 
diarrhea, decreased performance in 
athletes
Depending on the form, may be 
taken one to three times a day
Propranolol
Calcium channel blockers
Verapamil
Constipation and dizziness; hair loss Frequently started at low dosages 
and slowly increased. Taken twice a 
day; usually the first dose is taken in 
the morningDiltiazem HCl
Anticonvulsants
Valproic acid
Nausea, drowsiness, weight gain, 
tremors and rare liver failure; may 
cause birth defects
Frequently started at low dosages 
and slowly increased. Periodic blood 
tests required
Topiramate Rare: Glaucoma, kidney stone at high 
doses (>150 mg), weight loss, word 
finding difficulties
Frequently started at low dosages 
and slowly increased; may be taken 2 
to 3 times/daily
Gabapentin Generally well tolerated Usually started at low dosages and 
slowly increased; may be taken 2–3 
times/daily
Table reproduced and adapted from the original source [80].
*Other SSRIs include citalopram, escitalopram, fluvoxamine, paroxetine, sertraline.
**GI, gastrointestinal.
***EKG, electrocardiogram.
Table 5. Side effects of main first-line migraine preventive drugs.
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6. Primary cephalea treatment overuse and abuse statistics worldwide
Once a patient receives the diagnosis of migraine or any other primary headache, treatments 
usually become supervised by a medical team and patients are directed on what to do and 
what not to do regarding pharmacological therapy and although this group of patients car-
ries a certain risk for medication abuse or overuse, usually there are no major concerns unless 
the patient abandons regular control and supervised treatment. Unfortunately, up to 50% 
of migraine patients remain undiagnosed [81] and even worst, up to 82% of patients with a 
diagnosis of nonmigraine headache actually meet the major migraine criteria [82] leading to 
improper handling and medication.
Regarding chronic tension-type headaches, up to 40% of patients have not received a formal 
diagnosis and are not aware of what disease they are suffering from [83]; they often think they 
have a benign condition causing the self-medication of migraine rescue drugs (OTC painkill-
ers and analgesics) to become a trend, leading to the worsening of their underlying disorder.
On the other hand, a group of patients with a formal diagnosis of a primary headache dis-
order abandon follow-up due to lack of insurance, discouraging results or moving away to 
an area with no specialists with experience on headache treatment, keeping their treatment 
as something they do on their own, usually increasing dosing and dose intervals, leading to 
preventive and abortive medication overuse [84]. Aside from the above mentioned, there is 
another group of existing patients suffering from chronic daily headache affecting up to 5% of 
Over-the-counter medications for symptomatic relief
Drug name Symptoms relieved Precautions and possible side effects
Nonsteroidal anti-inflammatories
Aspirin Relief of fever and pain Do not use in children under 14 years 
of age due to the potential for Reye’s 
Syndrome
Side effects may include: heartburn, 
gastrointestinal (GI) bleeding, 
bronchospasm or constriction that 
causes narrowing of the airways, 
anaphylaxis and peptic ulcer
Acetaminophen Relief of fever and pain Few side effects, if taken as directed, 
although they may include: changes 
in blood counts and liver functions
Ibuprofen Relief of fever, pain and 
inflammation
Side effects may include 
gastrointestinal upset, GI bleeding, 
nausea, vomiting, rash and changes 
in liver function
Naproxen Sodium Headache pain relief Side effects may include GI upset, GI 
bleeding, nausea, vomiting, rash and 
changes in liver function
Table reproduced and adapted from the original source [80].
Table 6. Side effects of main migraine rescue drugs.
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the general population [85], self-medicating with over-the-counter painkillers and analgesics 
to deal with pain crisis, increasing the risk of evolution toward chronic headache [86] due to 
central nervous system sensitization [87].
Even when not included in the International Headache Society Classification of Headache, 
chronic daily headache is a common disorder defined by some authors as “a disorder where 
patients suffer very frequent headaches (15 or more days/month), including those headaches”, furthermore, 
“Chronic Daily Headache (CDH) may be divided into two main groups; Primary CDH is not related to 
any structural or systemic illness. Population based studies suggest that Chronic Tension Type Headache 
is the leading cause of primary CDH, on the other hand, Secondary CDH occurs 15 or more times a month 
or has some identifiable underlying cause [88]” (secondary CDH is summarized in Table 7).
Among all these patients “thirty-five percent overused simple analgesics, 22% ergotics, 12.5% 
opioids, and 2.7% triptans; the remaining 27.8% have overused different combinations” [28]. The 
major concern about these statistics is that although treatments may be helpful in the initial 
Chronic daily headache
Primary chronic daily headache
 Headache duration >4 hours
  Chronic migraine (previously transformed migraine)
  Chronic tension-type headache
  New daily persistent headache
  Hemicrania continua
 Headache duration <4 hours
  Cluster headache
  Paroxysmal hemicranias
  Hypnic headache
  Idiopathic stabbing headache
Secondary chronic daily headache
 Posttraumatic headache
 Cervical spine disorders
  Headache associated with vascular disorders (arteriovenous malformation, arteritis including giant cell arteritis, 
dissection, and subdural hematoma)
  Headache associated with nonvascular intracranial disorders [intracranial hypertension, infection (EBV, HIV), 
neoplasm]
  Other (temporomandibular joint disorder, sinus infection)
Abbreviations: EBV, Epstein-Barr virus; HIV, human immunodeficiency virus.
Table reproduced and adapted from the original source [89].
Table 7. Chronic daily headache causes.
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stages, their chronic, unsupervised use and abuse tends to lead toward pain chronification; 
increasing the number of pain crises, intensity of pain, and resistance to regular analgesic 
dosing. Moreover, relapsing after medication withdrawal is still a major issue regarding 
both preventive and rescue primary headache treatments [90]. How many patients progress 
toward chronification will vary depending on the abused medication, according to Bigal 
“available data suggest that opioids induce migraine chronification (progression), and the effect is 
dose dependent (critical dose around 8 days of exposure per month) and more pronounced in men. 
Barbiturates also induce migraine progression, and the effect is dose dependent (critical dose around 
5 days of exposure per month) and more pronounced in women. Triptans induce migraine progres-
sion only in those with high migraine frequency at baseline (10–14 days per month), but not overall. 
NSAIDs protect against migraine progression unless individuals have 10 or more headache days per 
month (when they become inducers, rather than protective). Finally, caffeine-containing over-the-
counter products increase risk of progression” [91], thus each available drug used must be moni-
tored individually in order to avoid overuse and abuse-related complications. Why and how 
primary headaches progress to chronification because of treatment abuse is still partially 
unknown and a field of very active research.
7. Underlying pathways for headache chronification following 
treatment abuse
It is a well-known fact that chronic exposure to pain treatment [92] as well suffering from 
chronic pain, especially chronic headache, increase the risk of chronic pain development due 
to “reduced endogenous inhibition of pain, implying that an individual’s processing of pain-related 
information changes with the onset of the syndrome” [93]; however, the underlying mechanisms 
behind it still remain partially unknown.
Among the painful syndromes, chronic headache is one of those most commonly associated 
with long lasting analgesic consumption, termed medication overuse headache (MOH) when 
it occurs, a pathological entity “defined by the International Headache Society as a headache 
induced by the overuse of analgesics, triptans, or other acute headache compounds whose 
detailed pathophysiology is still unknown” [94]. Current knowledge indicates that it can take 
up to 25 years for a chronic pain condition to develop after the use of chronic analgesics MOH 
[95] with strong evidence to support that chronic use of analgesics is a good predictor of an 
increased occurrence of both migraine and nonmigrainous headaches within the next 11 years, 
with a combined risk ratio of 19.6%, which is extremely high when compared to only 3.1% for 
patients who do not overuse analgesic treatments [96]. But analgesics are not the only medica-
tions involved in MOH, ergots and triptans also play a key role in MOH, with a shorter interval 
between initial treatment and development of induced chronic headache. “The delay between 
first intake and these attacks is the shortest for triptans (1–2 years), longer for ergots (3–5 years)” 
[97] and the longest for analgesics as it was previously mentioned. In this regard, the risk of 
induced chronic headache is lower for triptans (i.e., sumatriptan) than for ergotamine [98], 
which is good news for patients since triptans are the drug of choice before ergotamine. The 
problem when trying to establish a prevention/treatment strategy for drug-induced headache 
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as well as MOH arises from the fact that different drugs are involved in their development; 
hence, there is no single way to explain the related mechanisms or physiopathology. Even 
more complex is the attempt to establish the diagnosis of MOH or drug-induced headache 
since most of the time the clinical profile of the primary entity is the same as the induced one, 
making it very difficult to establish a difference among them and even worse, to determine 
when the primary headache has ended and MOH appeared. A single approach to establish 
such differences is symptom improvement with treatment withdrawal [99]; the headache was 
drug induced and not of a primary origin and once the trigger (the drug) has ceased, symp-
toms should improve.
Figure 4 shows a schema of what happens during drug-induced headache and how the diag-
nosis may be addressed regardless of the underlying molecular mechanisms.
Of note, opioids have been found to be one of the most problematic drugs found to induce 
chronic headache, regardless of the purpose of their use whether it be chronic headache 
or any other chronic pain condition such as back pain, oncologic pain, and so on. The 
underlying mechanism seems to be “the activation of toll-like receptor-4 on glial cells, result-
ing in a pro- inflammatory state that manifests clinically as increased pain” [101], such activa-
tion may explain not only the development of MOH but also of the transformation to 
migraine [102].
Another hypothesis sustained by preclinical research is the presence of neuroadaptive 
changes related to chronic use of opiates; such changes “include increased expression of calci-
tonin gene-related peptide (CGRP) in trigeminal primary afferent neurons. Centrally, they include 
increased excitatory neurotransmission at the level of the dorsal horn and nucleus caudalis. Critically, 
these neuroadaptive changes persist for long periods of time and the evoked release of CGRP is enhanced 
following morphine pretreatment [103]; all these changes lead to Induced Hyperalgesia [101, 104] and 
thus Headache Chronification.”
But opiates are not the only molecules associated with MOH, there is also strong evi-
dence suggesting that combined analgesics as well as joined ergotamine-caffeine prepara-
tions may induce a metabolic decrease in several brain areas, especially the orbitofrontal 
Figure 4. Drug-induced headache vicious circle [100].
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cortex leading to a decrease in intrinsic pain downregulation circuits and the development of 
chronic headaches such as MOH and modified migraine (MM) [105]. Such metabolic changes 
may be associated with the sensitization of the trigeminal and somatic nociceptive systems; 
another possible path leading to MOH was demonstrated by Ayzenberg et al. on triptan-
induced MOH [106].
Furthermore, the mechanisms stated earlier may be connected to others both centrally and 
peripherally by a complex net of interactions currently unknown but feasible such as “upregu-
lation of calcitonin gene–related peptide, substance P, and nitric oxide synthase in trigeminal ganglia; 
expansion of receptive field and decreased nociceptive threshold of central trigeminal neurons; decrease 
in diffuse noxious inhibitory control; and increased susceptibility to develop cortical spreading depres-
sion (CSD). These changes indicate an increase in excitability of cortical and trigeminal neurons. The 
neuronal hyperexcitability may be the result of derangement of a central, possibly serotonin (5-HT)-
dependent, modulating control system. Experiments with animals with low 5-HT showed that the 
processes of CSD and trigeminal nociception are enhanced in this condition” [107] as it has been 
demonstrated by Bongsebandhu et al. in animal models.
The available information clearly supports the theory that analgesics and painkillers play 
an active role in the chronification of headache, which is a real concern for the medi-
cal community considering the high number of available over-the-counter analgesics. 
Furthermore, primary therapies such as triptans are also involved in MOH development 
after chronic use and there is even weaker evidence to explain the underlying pathways 
that cause this occurrence. At the moment the most probable mechanism of triptan-
induced MOH is “induction of neural adaptations that result in a state of latent sensitization, 
which might increase sensitivity to migraine triggers” [108], in addition, “triptan administration 
promotes increased expression of neuronal nitric oxide synthase in dural afferents, which is critical 
for enhanced sensitivity to environmental stress, which is a biological basis for increased frequency 
of headache following“ [109].
Certainly, current knowledge regarding MOH and other types of headache chronifica-
tion caused by the use of therapy is still lacking although the results from many research 
reports are available. However, until a deeper scientific understanding is available 
regarding this relatively new entity, it becomes necessary to improve the diagnostic cri-
teria and methods, enhance treatment protocols, and provide proper monitoring not only 
to chronic primary headache patients but also to each one suffering from a chronic pain 
condition.
Until a more precise and wider scope of information is available, prevention remains the 
best, most cost-effective option used to prevent headache treatment abuse-related complica-
tions. When the disorder of MOH and drug-induced headache presents, the main treatment 
must be treatment withdrawal and even then the discussion on what is the best withdrawal 
method (stationary vs. ambulatory) still remains inconclusive [110]; as a preventive strategy, 
drug combinations must be avoided as much as possible and high-risk patients who develop 
MOH must be regularly evaluated to ensure that no late complications are showing up during 
long-term treatment.
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